BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 18157384)

  • 1. [Growth hormone (GH) deficiency treatment in children: comparison between uses of pen versus bottles/syringes on GH administration].
    Marchisotti FG; Carvalho LR; Berger K; Arnhold IJ; Mendonça BB
    Arq Bras Endocrinol Metabol; 2007 Oct; 51(7):1093-6. PubMed ID: 18157384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ease of use and acceptability of a new pen device for the administration of growth hormone therapy in pediatric patients: an open-label, uncontrolled usability test.
    Fuchs GS; Mikkelsen S; Knudsen TK; Kappelgaard AM
    Clin Ther; 2009 Dec; 31(12):2906-14. PubMed ID: 20110030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-year efficacy and safety of LB03002, a once-weekly sustained-release growth hormone (GH) preparation, in prepubertal children with GH deficiency (GHD).
    Péter F; Bidlingmaier M; Savoy C; Ji HJ; Saenger PH
    J Clin Endocrinol Metab; 2012 Feb; 97(2):400-7. PubMed ID: 22162481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth hormone therapy with a new delivery system.
    Jørgensen JT; Susgaard S
    Indian J Pediatr; 1991; 58 Suppl 1():43-50. PubMed ID: 1824374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of growth hormone treatment on serum bone alkaline phosphatase in growth hormone deficient children.
    Korpal-Szczyrska M; Balcerska A
    Pediatr Endocrinol Diabetes Metab; 2008; 14(4):211-4. PubMed ID: 19239787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intuitiveness, ease of use, and preference of a prefilled growth hormone injection pen: a noninterventional, randomized, open-label, crossover, comparative usability study of three delivery devices in growth hormone-treated pediatric patients.
    Pfützner A; Hartmann K; Winter F; Fuchs GS; Kappelgaard AM; Rohrer TR
    Clin Ther; 2010 Oct; 32(11):1918-34. PubMed ID: 21095487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy and safety of recombinant human growth hormone solution in children with growth hormone deficiency in China: a multicenter trial].
    Hou L; Luo XP; Du ML; Ma HM; Gong CX; Li YC; Shen SX; Zhao ZH; Liang L; Dong GP; Yan CY; Du HW
    Zhonghua Er Ke Za Zhi; 2009 Jan; 47(1):48-52. PubMed ID: 19573383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth hormone (GH) dosing during catch-up growth guided by individual responsiveness decreases growth response variability in prepubertal children with GH deficiency or idiopathic short stature.
    Kriström B; Aronson AS; Dahlgren J; Gustafsson J; Halldin M; Ivarsson SA; Nilsson NO; Svensson J; Tuvemo T; Albertsson-Wikland K
    J Clin Endocrinol Metab; 2009 Feb; 94(2):483-90. PubMed ID: 19001519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient acceptance of Nordiject: a new drug delivery system for growth hormone.
    Jørgensen JT; Mortensen HB; Jørgensen JO
    DICP; 1991 Jun; 25(6):585-8. PubMed ID: 1877265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth hormone (GH) dose-dependent IGF-I response relates to pubertal height gain.
    Lundberg E; Kriström B; Jonsson B; Albertsson-Wikland K;
    BMC Endocr Disord; 2015 Dec; 15():84. PubMed ID: 26682747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of long-term growth hormone therapy in short non-growth hormone-deficient children.
    Schena L; Meazza C; Pagani S; Paganelli V; Bozzola E; Tinelli C; Buzi F; Bozzola M
    J Pediatr Endocrinol Metab; 2017 Feb; 30(2):197-201. PubMed ID: 28099132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased GH dose after the catch-up growth period maintains metabolic outcome in short prepubertal children with and without classic GH deficiency.
    Decker R; Albertsson-Wikland K; Kriström B; Halldin M; Dahlgren J
    Clin Endocrinol (Oxf); 2012 Sep; 77(3):407-15. PubMed ID: 22417085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient preference for a new growth hormone injection device: results of an open-label study in Japanese pediatric patients.
    Kappelgaard AM; Mikkelsen S; Knudsen TK; Fuchs GS
    J Pediatr Endocrinol Metab; 2011; 24(7-8):489-96. PubMed ID: 21932587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is the growth outcome of children with idiopathic short stature and isolated growth hormone deficiency following treatment with growth hormone and a luteinizing hormone-releasing hormone agonist superior to that obtained by GH alone?
    Colmenares A; González L; Gunczler P; Lanes R
    J Pediatr Endocrinol Metab; 2012; 25(7-8):651-7. PubMed ID: 23155689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth hormone administration by means of an injection pen.
    Jørgensen JO; Møller J; Jensen FS; Jørgensen JT; Christiansen JS
    Pharmacol Toxicol; 1989 Aug; 65(2):96-9. PubMed ID: 2813289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Norditropin SimpleXx: a liquid human growth hormone formulation, a pen system and an auto-insertion device.
    Müller J; Skakkebaek NE; Jacobsen BB; Keller E; Heinrich U; Hartmann K; Hokken-Koelega AC; Delemarre van de Waal HA
    Horm Res; 1999; 51 Suppl 3():109-12. PubMed ID: 10592453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 24-month use of once-weekly GH, LB03002, in prepubertal children with GH deficiency.
    Khadilkar V; Radjuk KA; Bolshova E; Khadgawat R; El Kholy M; Desai M; Peterkova V; Mericq V; Kratzsch J; Siepl EC; Martin D; Lopez P; Ji HJ; Bae YJ; Lee JH; Saenger PH
    J Clin Endocrinol Metab; 2014 Jan; 99(1):126-32. PubMed ID: 24170106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The response to growth hormone treatment in prepubertal children with growth hormone deficiency in Japan: Comparing three consecutive years of treatment data of The Foundation for Growth Science in Japan between the 1990s and 2000s.
    Isojima T; Hasegawa T; Yokoya S; Tanaka T
    Endocr J; 2017 Sep; 64(9):851-858. PubMed ID: 28679975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label acceptability study of Norditropin SimpleXx--a new liquid growth hormone formulation.
    Stanhope R; Buchanan C; Butler G; Costigan C; Dunger D; Greene S; Hoey H; Hughes I; Kelnar C; Kirk J; Komulainen J; Lowry M; Warner J
    J Pediatr Endocrinol Metab; 2001 Jun; 14(6):735-40. PubMed ID: 11453523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of treatment adherence with growth hormone by easypod™ device: experience of an Italian centre.
    Maggio MC; Vergara B; Porcelli P; Corsello G
    Ital J Pediatr; 2018 Sep; 44(1):113. PubMed ID: 30261918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.